(MENAFN- GlobeNewsWire - Nasdaq) WARREN, N.J., Sept.04, 2019(GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019, in New York City.
| Bellerophon Presentation Details |
| Date: | | Tuesday, September 10, 2019 |
| Time: | | 2:10 – 2:35 PM ET |
| Webcast: | | http://wsw.com/webcast/hcw5/blph/ |
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com .
| Contacts |
| At Bellerophon: | | At LifeSci Advisors: |
| Fabian Tenenbaum, Chief Executive Officer | | Brian Ritchie |
| (908) 574-4767 | | (212) 915-2578 |
| | | |
MENAFN0409201900703653ID1098963964
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.